Collectively, our findings demonstrate that SCORT‐CasRx‐pre‐gHoxB13 treatment decreases metastatic tumor growth and angiogenesis while promoting apoptosis of both AR+ and AR‐ CRPC. This evidence concerns the gene AR and neoplasm.